Search

MicroRNAs (miRNAs) are crucial regulators in various pathological and physiological processes, and their misregulation is a hallmark of many diseases. In this study, we introduce an advanced DNA nanomachine using split-type molecular beacons (STMBs) for sensitive detection of miR-21, a key biomarker in cancer diagnostics. Utilizing an innovative STMB-mediated cascade strand displacement amplification (STMB-CSDA) technique, our approach offers a powerful means for the precise quantification of miRNAs, using miR-21 as a primary example. The system operates through target-induced linkage of STMBs, initiating a series of strand displacement amplifications resulting in exponential signal amplification. Coupled with the precision of T4 DNA ligase, this mechanism translates minimal miRNA presence into significant fluorescence signals, offering detection sensitivity as low as 5.96 pM and a dynamic range spanning five orders of magnitude. Characterized by its high specificity, which includes the ability to identify single-base mismatches, along with its user-friendly design, our method represents a significant leap forward in miRNA analysis and molecular diagnostics. Its successful application in examining total RNA from cancer cells and clinical serum samples demonstrates its immense potential as a groundbreaking tool for early cancer detection and gene expression studies, paving the way for the next generation of non-invasive diagnostics in personalized healthcare., Competing Interests: Declaration of competing interest No conflict of interest exits in the submission of this manuscript, and manuscript is approved by all authors for publication. We declare that the work described was original research that has not been published previously, and not under consideration for publication elsewhere, in whole or in part. We agree to pay page charges and color publication fees if our paper is accepted., (Copyright © 2024 Elsevier B.V. All rights reserved.)

Background: Human vision has inspired significant advancements in computer vision, yet the human eye is prone to various silent eye diseases. With the advent of deep learning, computer vision for detecting human eye diseases has gained prominence, but most studies have focused only on a limited number of eye diseases., Results: Our model demonstrated a reduction in inherent bias and enhanced robustness. The fused network achieved an Accuracy of 0.9237, Kappa of 0.878, F1 Score of 0.914 (95% CI [0.875-0.954]), Precision of 0.945 (95% CI [0.928-0.963]), Recall of 0.89 (95% CI [0.821-0.958]), and an AUC value of ROC at 0.987. These metrics are notably higher than those of comparable studies., Conclusions: Our deep neural network-based model exhibited improvements in eye disease recognition metrics over models from peer research, highlighting its potential application in this field., Methods: In deep learning-based eye recognition, to improve the learning efficiency of the model, we train and fine-tune the network by transfer learning. In order to eliminate the decision bias of the models and improve the credibility of the decisions, we propose a model decision fusion method based on the D-S theory. However, D-S theory is an incomplete and conflicting theory, we improve and eliminate the existed paradoxes, propose the improved D-S evidence theory(ID-SET), and apply it to the decision fusion of eye disease recognition models., (© 2024. The Author(s).)

The present study evaluated the role of annexin A1 (ANXA1) in the treatment of acute radiation-induced lung injury (RILI) and investigated the mechanism of its action. The expression of ANXA1, interleukin-6 (IL-6) and myeloperoxidase (MPO) in the plasma of patients with RILI prior to and following hormonotherapy was assessed by enzyme-linked immunosorbent assay. The association of plasma ANXA1 concentration with clinical effect, and the correlation between the expression of ANXA1 and that of IL-6 and MPO were evaluated. ANXA1 was overexpressed or knocked down in a macrophage cell line, and its impact on IL-6 and MPO expression was measured. Following glucocorticoid hormonotherapy, patients with RILI exhibited a higher plasma concentration of ANXA1 compared with that prior to treatment, while IL-6 and MPO levels were lower. The concentration of ANXA1 in plasma was negatively correlated with IL-6 and MPO levels, with a correlation coefficient of -0.492 and -0.437, respectively (P<0.001). The increasing concentration of ANXA1 in plasma following treatment was associated with the clinical effect in patients with RILI (P=0.007). The expression levels of of IL-6 and MPO were inhibited both in the cytoplasm and in the culture solution, when ANXA1 expression was upregulated in a macrophage cell line. In conclusion, ANXA1 inhibited the synthesis and secretion of IL-6 and MPO inflammatory cytokines, indicating that ANXA1 may have therapeutic potential as a treatment target for RILI.

Background and Aim: This study was designated to assess the diagnostic value of 99 Tc M -2-(2-methyl-5-nitro-1 H -imidazol-1-yl) ethyl dihydrogen phosphate ( 99 Tc M -MNLS) hypoxia imaging and its evaluation performance for radiotherapy efficacy in patients with non-small-cell lung cancer (NSCLC)., Patients and Methods: A total of 61 patients with NSCLC were selected for this study. All patients were injected with 99 Tc M -MNLS within 1 week prior to radiotherapy and they were injected with 99 Tc M -MNLS again 3 months after radiotherapy. Qualitative analysis along with semiquantitative analysis results were obtained from hypoxia imaging. Meanwhile, the effect of radiotherapy on patients with NSCLC was evaluated based on the solid tumor curative effect evaluation standard. Finally, SPSS 19.0 statistical software was implemented for statistical analysis., Results: There was no significant difference in age or sex between the NSCLC patient group and benign patient group ( P >0.05). 99 Tc M -MNLS was selectively concentrated in tumor tissues with a clear imaging in 24 hours. Results from both qualitative analysis and semiquantitative analysis indicated that the sensitivity and specificity of 99 Tc M -MNLS hypoxia imaging in diagnosing NSCLC were 93.8% and 84.6% and 72.9% and 100%, respectively. Moreover, the receiver operating characteristic curve provided evidence that 99 Tc M -MNLS hypoxia imaging was a powerful diagnostic tool in distinguishing malignant lung cancer from benign lesions. As suggested by 24-hour imaging, the tumor-to-normal ratio of patients in the 99 Tc M -MNLS high-intake group and low-intake group had a decline of 24.7% and 14.4% after radiotherapy, respectively. The decline in the tumor-to-normal ratio between the two dosage groups was significantly different ( P <0.05)., Conclusion: 99 Tc M -MNLS hypoxia imaging had reliable values in both diagnosing NSCLC and evaluating therapeutic effects of radiotherapy on patients with NSCLC., Competing Interests: The authors report no conflicts of interest in this work.